Rating Change
Cantor Fitzgerald analysts initiated coverage on Ovid Therapeutics Inc. (NASDAQ:OVID) with a rating of Overweight on October 09, 2026.
new coverageNASDAQ:OVID
Cantor Fitzgerald Initiates Coverage on Ovid Therapeutics Inc. (OVID) with Overweight
Cantor Fitzgerald analysts initiated coverage on Ovid Therapeutics Inc. (NASDAQ:OVID) with a rating of Overweight on October 09, 2026.
At publication ·
What changed
Ovid Therapeutics Inc. (NASDAQ:OVID) · new coverage
- Firm
- Cantor Fitzgerald
- Rating
- Overweight
- Price at event
- $2.45
- Market capitalization
- $117.3M
At a glance
Key takeaways
- Cantor Fitzgerald initiated coverage of Ovid Therapeutics with an Overweight rating on October 9, 2026.
- The stock trades at $2.45 with a market capitalization of $117.3 million and gained 40.1% over the past 52 weeks.
Market Context
Ovid Therapeutics Inc. operates in the Healthcare sector. The stock currently trades at $2.45 with a market capitalization of $117.3M. The stock has gained 40.1% over the past 52 weeks.
Analyst coverage from Cantor Fitzgerald provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Ovid Therapeutics Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Ovid Therapeutics Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 09, 2026 | Cantor Fitzgerald | Overweight | N/A |
| Oct 06, 2026 | Guggenheim | Buy | N/A |
| Oct 05, 2026 | Guggenheim | Buy | N/A |
| Sep 11, 2026 | HC Wainwright & Co. | Buy | N/A |
| Aug 03, 2026 | Oppenheimer | Outperform | N/A |
Related Tools: Analyst Ratings Dashboard | View OVID Stock Page
Frequently Asked Questions
What does the Overweight rating mean for OVID?
A rating of Overweight from Cantor Fitzgerald reflects the analyst's outlook on Ovid Therapeutics Inc. (NASDAQ:OVID). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the OVID forecast page.